NASDAQ:FLGT Fulgent Genetics (FLGT) Stock Price, News & Analysis $20.36 -0.05 (-0.24%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$20.34 -0.02 (-0.12%) As of 08/8/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Fulgent Genetics Stock (NASDAQ:FLGT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Fulgent Genetics alerts:Sign Up Key Stats Today's Range$20.01▼$20.5650-Day Range$17.18▼$21.8152-Week Range$14.57▼$24.61Volume224,313 shsAverage Volume379,759 shsMarket Capitalization$623.22 millionP/E RatioN/ADividend YieldN/APrice Target$25.33Consensus RatingModerate Buy Company Overview Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California. Read More Fulgent Genetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreFLGT MarketRank™: Fulgent Genetics scored higher than 76% of companies evaluated by MarketBeat, and ranked 232nd out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingFulgent Genetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageFulgent Genetics has only been the subject of 2 research reports in the past 90 days.Read more about Fulgent Genetics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Fulgent Genetics are expected to decrease in the coming year, from ($0.85) to ($1.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fulgent Genetics is -12.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fulgent Genetics is -12.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFulgent Genetics has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.48% of the float of Fulgent Genetics has been sold short.Short Interest Ratio / Days to CoverFulgent Genetics has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Fulgent Genetics has recently decreased by 3.63%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFulgent Genetics does not currently pay a dividend.Dividend GrowthFulgent Genetics does not have a long track record of dividend growth. Sustainability and ESG4.1 / 5Environmental Score-0.67 Percentage of Shares Shorted9.48% of the float of Fulgent Genetics has been sold short.Short Interest Ratio / Days to CoverFulgent Genetics has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Fulgent Genetics has recently decreased by 3.63%, indicating that investor sentiment is improving. News and Social Media3.1 / 5News Sentiment0.64 News SentimentFulgent Genetics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Fulgent Genetics this week, compared to 3 articles on an average week.Search InterestOnly 6 people have searched for FLGT on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows1 people have added Fulgent Genetics to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Fulgent Genetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $59,812.00 in company stock.Percentage Held by Insiders31.76% of the stock of Fulgent Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions48.06% of the stock of Fulgent Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fulgent Genetics' insider trading history. Receive FLGT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter. Email Address FLGT Stock News HeadlinesFulgent Genetics (NASDAQ:FLGT) Upgraded to Buy at UBS GroupAugust 8 at 2:25 AM | americanbankingnews.comFulgent Genetics (NASDAQ:FLGT) Given a $21.00 Price Target by Piper Sandler AnalystsAugust 7 at 2:53 AM | americanbankingnews.comREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!).August 9 at 2:00 AM | Weiss Ratings (Ad)UBS Upgrades Fulgent Genetics (FLGT)August 6 at 4:55 AM | msn.comFulgent Genetics (NASDAQ:FLGT) Shares Down 3.4% on Analyst DowngradeAugust 5, 2025 | americanbankingnews.comFulgent Genetics’ Earnings Call Highlights Growth and OptimismAugust 4, 2025 | theglobeandmail.comFulgent Genetics (NASDAQ:FLGT) Shares Gap Up After Better-Than-Expected EarningsAugust 3, 2025 | americanbankingnews.comFulgent Genetics, Inc. (NASDAQ:FLGT) Q2 2025 Earnings Call TranscriptAugust 2, 2025 | insidermonkey.comSee More Headlines FLGT Stock Analysis - Frequently Asked Questions How have FLGT shares performed this year? Fulgent Genetics' stock was trading at $18.47 at the beginning of the year. Since then, FLGT stock has increased by 10.2% and is now trading at $20.36. How were Fulgent Genetics' earnings last quarter? Fulgent Genetics, Inc. (NASDAQ:FLGT) posted its quarterly earnings results on Friday, August, 1st. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.30. Fulgent Genetics's revenue for the quarter was up 15.2% compared to the same quarter last year. Read the conference call transcript. Does Fulgent Genetics have any subsidiaries? Fulgent Genetics subsidiaries include Inform Diagnostics, CSI, Cytometry Specialists Inc., FF Gene Biotech, Fulgent Investment Development Limited, and Fulgent Therapeutics LLC. When did Fulgent Genetics IPO? Fulgent Genetics (FLGT) raised $60 million in an initial public offering (IPO) on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers. Who are Fulgent Genetics' major shareholders? Fulgent Genetics' top institutional shareholders include Acadian Asset Management LLC (3.65%), Geode Capital Management LLC (1.68%), Connor Clark & Lunn Investment Management Ltd. (1.00%) and Allianz Asset Management GmbH (0.14%). Insiders that own company stock include Hanlin Gao, Ming Hsieh, Jian Xie and Paul Kim. View institutional ownership trends. How do I buy shares of Fulgent Genetics? Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Fulgent Genetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fulgent Genetics investors own include NVIDIA (NVDA), CrowdStrike (CRWD), Meta Platforms (META), Advanced Micro Devices (AMD), PayPal (PYPL), Broadcom (AVGO) and Arista Networks (ANET). Company Calendar Last Earnings8/01/2025Today8/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MEDICAL INFO SYS Sub-IndustryHealthcare Current SymbolNASDAQ:FLGT CIK1674930 Webwww.fulgentgenetics.com Phone(626) 350-0537Fax626-454-1667Employees1,313Year Founded2011Price Target and Rating Average Price Target for Fulgent Genetics$25.33 High Price Target$30.00 Low Price Target$21.00 Potential Upside/Downside+24.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$42.71 million Net Margins-16.83% Pretax Margin-19.73% Return on Equity-2.26% Return on Assets-2.10% Debt Debt-to-Equity RatioN/A Current Ratio6.01 Quick Ratio6.32 Sales & Book Value Annual Sales$283.47 million Price / Sales2.20 Cash FlowN/A Price / Cash FlowN/A Book Value$36.32 per share Price / Book0.56Miscellaneous Outstanding Shares30,610,000Free Float20,888,000Market Cap$623.22 million OptionableOptionable Beta0.83 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:FLGT) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulgent Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulgent Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.